Current challenges for HER2 testing in diagnostic pathology: State of the art and controversial issues

Frontiers in Oncology

Volumn 3 MAY, Issue , 2013, Pages

  Sapino, Anna ^a   Goia, Margherita ^a   Recupero, Daniele ^a   Marchiò, Caterina ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

CEP17 amplification; Diagnosis; HER2; HER2 mutations; Test; Therapy; Truncated HER2

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LAPATINIB; PERTUZUMAB; PHENADOXONE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE;

ARTICLE; BREAST CANCER; CHROMOSOME; DIAGNOSTIC PROCEDURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HUMAN; IMMUNOHISTOCHEMISTRY; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION;

EID: 84891058756     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00129     Document Type: Article

References (79)

1. Anido, J., Scaltriti, M., Bech Serra, J. J., Santiago Josefat, B., Todo, F. R., and Baselga, J. (2006). Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J. 25, 3234-3244.
2. Arribas, J., Baselga, J., Pedersen, K., and Parra-Palau, J. L. (2011). p95HER2 and breast cancer. Cancer Res. 71, 1515-1519.
3. Banerji, S., Cibulskis, K., Rangel-Escareno, C., Brown, K. K., Carter, S. L., and Frederick, A. M. (2012). Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405-409.
4. Baselga, J., Cortes, J., Kim, S. B., Im, S. A., Hegg, R., and Im, Y. H. (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N. Engl. J. Med. 366, 109-119.
5. Birner, P., Oberhuber, G., Stani, J., Reithofer, C., Samonigg, H., and Hausmaninger, H. (2001). Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin. Cancer Res. 7, 1669-1675.
6. Bose, R., Kavuri, S. M., Searleman, A. C., Shen, W., Shen, D., and Koboldt, D. C. (2013). Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov. 3, 224-237.
7. Brunelli, M., Manfrin, E., Martignoni, G., Bersani, S., Remo, A., and Reghellin, D. (2008). HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. Am. J. Clin. Pathol. 129, 907-911.
8. Bussolati, G., Annaratone, L., Medico, E., D'Armento, G., and Sapino, A. (2011). Formalin fixation at low temperature better preserves nucleic acid integrity. PLoS ONE 6:e21043. doi:10.1371/journal.pone.0021043
9. Bussolati, G., Montemurro, F., Righi, L., Donadio, M., Aglietta, M., and Sapino, A. (2005). A modified Trastuzumab antibody for the immunohistochemical detection of HER-2 overexpression in breast cancer. Br. J. Cancer 92, 1261-1267.
10. Christianson, T. A., Doherty, J. K., Lin, Y. J., Ramsey, E. E., Holmes, R., and Keenan, E. J. (1998). NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res. 58, 5123-5129.
11. Codony-Servat, J., Albanell, J., Lopez-Talavera, J. C., Arribas, J., and Baselga, J. (1999). Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. Cancer Res. 59, 1196-1201.
12. Comanescu, M., Annaratone, L., D'Armento, G., Cardos, G., Sapino, A., and Bussolati, G. (2012). Critical steps in tissue processing in histopathology. Recent Pat. DNA Gene Seq. 6, 22-32.
13. Fabi, A., Di Benedetto, A., Metro, G., Perracchio, L., Nistico, C., and Di Filippo, F. (2011). HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin. Cancer Res. 17, 2055-2064.
14. Farshid, G., Cheetham, G., Davies, R., Moore, S., and Rudzki, Z. (2011). Validation of the multiplex ligation-dependent probe amplification (MLPA) technique for the determination of HER2 gene amplification in breast cancer. Diagn. Mol. Pathol. 20, 11-17.
15. Gancberg, D., Di Leo, A., Cardoso, F., Rouas, G., Pedrocchi, M., and Paesmans, M. (2002). Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann. Oncol. 13, 1036-1043.
16. Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., and Pienkowski, T. (2006). Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733-2743.
17. Gong, Y., Booser, D. J., and Sneige, N. (2005). Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma. Cancer 103, 1763-1769.
18. Guarneri, V., Frassoldati, A., Bottini, A., Cagossi, K., Bisagni, G., and Sarti, S. (2012). Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J. Clin. Oncol. 30, 1989-1995.
19. Gunn, S., Yeh, I. T., Lytvak, I., Tirtorahardjo, B., Dzidic, N., and Zadeh, S. (2010). Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexity. BMC Cancer 10:396. doi:10.1186/1471-2407-10-396
20. Hicks, D. G., and Tubbs, R. R. (2005). Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelines. Hum. Pathol. 36, 250-261.
21. Hurvitz, S. A., Dirix, L., Kocsis, J., Bianchi, G. V., Lu, J., and Vinholes, J. (2012). Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J. Clin. Oncol. 31, 1157-1163.
22. Isola, J., Tanner, M., Forsyth, A., Cooke, T. G., Watters, A. D., and Bartlett, J. M. (2004). Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin. Cancer Res. 10, 4793-4798.
23. Jacobs, T. W., Gown, A. M., Yaziji, H., Barnes, M. J., and Schnitt, S. J. (1999). Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J. Clin. Oncol. 17, 1983-1987.
24. Jankowski, S., Currie-Fraser, E., Xu, L., and Coffa, J. (2008). Multiplex ligation-dependent probe amplification analysis on capillary electrophoresis instruments for a rapid gene copy number study. J. Biomol. Tech. 19, 238-243.
25. Kan, Z., Jaiswal, B. S., Stinson, J., Janakiraman, V., Bhatt, D., and Stern, H. M. (2010). Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 466, 869-873.
26. Kent, S. P., Ryan, K. H., and Siegel, A. L. (1978). Steric hindrance as a factor in the reaction of labeled antibody with cell surface antigenic determinants. J. Histochem. Cytochem. 26, 618-621.
27. Kozlowski, P., Jasinska, A. J., and Kwiatkowski, D. J. (2008). New applications and developments in the use of multiplex ligation-dependent probe amplification. Electrophoresis 29, 4627-4636.
28. Lee, A. H., Key, H. P., Bell, J. A., Hodi, Z., and Ellis, I. O. (2011). Breast carcinomas with borderline (2+) HER2 immunohistochemistry: percentage of cells with complete membrane staining for HER2 and the frequency of HER2 amplification. J. Clin. Pathol. 64, 490-492.
29. Liu, X., Fridman, J. S., Wang, Q., Caulder, E., Yang, G., and Covington, M. (2006). Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab. Cancer Biol. Ther. 5, 648-656.
30. Loibl, S., Bruey, J., and Von Minckwitz, G. (2011). Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: a translational investigation from the neoadjuvant GeparQuattro study. J. Clin. Oncol. 29(Suppl.), :abstr. 530.
31. Ma, Y., Lespagnard, L., Durbecq, V., Paesmans, M., Desmedt, C., and Gomez-Galdon, M. (2005). Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin. Cancer Res. 11, 4393-4399.
32. Marchio, C., Lambros, M. B., Gugliotta, P., Di Cantogno, L. V., Botta, C., and Pasini, B. (2009). Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis. J. Pathol. 219, 16-24.
33. Marchiò, C., and Reis-Filho, J. S. (2008). Molecular diagnosis in breast cancer. Diagn. Histopathol. (Oxf.) 14, 202-213.
34. Marchio, C., and Sapino, A. (2011). The pathologic complete response open question in primary therapy. J. Natl. Cancer Inst. Monographs 2011, 86-90.
35. Matthiesen, S. H., and Hansen, C. M. (2012). Fast and non-toxic in situ hybridization without blocking of repetitive sequences. PLoS ONE 7:e40675. doi:10.1371/journal.pone.0040675
36. Miller, D. V., Jenkins, R. B., Lingle, W. L., Davidson, N. E., Kaufman, P. A., and Martino, S. (2004). Focal HER2/neu amplified clones partially account for discordance between immunohistochemistry and fluorescence in-situ hybridization results: data from NCCTG N9831 Intergroup Adjuvant Trial. J. Clin. Oncol. 22, 568.
37. Moelans, C. B., de Weger, R. A., Van der Wall, E., and van Diest, P. J. (2011a). Current technologies for HER2 testing in breast cancer. Crit. Rev. Oncol. Hematol. 80, 380-392.
38. Moelans, C. B., Reis-Filho, J. S., and van Diest, P. J. (2011b). Implications of rarity of chromosome 17 polysomy in breast cancer. Lancet Oncol. 12, 1087-1089.
39. Moelans, C. B., de Weger, R. A., and van Diest, P. J. (2010). Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification. Breast Cancer Res. Treat. 120, 1-7.
40. Moerland, E., van Hezik, R. L., van der Aa, T. C., van Beek, M. W., and van den Brule, A. J. (2006). Detection of HER2 amplification in breast carcinomas: comparison of multiplex ligation-dependent probe amplification (MLPA) and fluorescence in situ hybridization (FISH) combined with automated spot counting. Cell. Oncol. 28, 151-159.
41. Molina, M. A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., and Baselga, J. (2001). Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61, 4744-4749.
42. Molina, M. A., Saez, R., Ramsey, E. E., Garcia-Barchino, M. J., Rojo, F., and Evans, A. J. (2002). NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin. Cancer Res. 8, 347-353.
43. Oakman, C., Sapino, A., Marchio, C., Pestrin, M., Biganzoli, L., and Di Leo, A. (2010). Chemotherapy with or without trastuzumab. Ann. Oncol. 21(Suppl. 7), vii112-vii119.
44. Ohlschlegel, C., Zahel, K., Kradolfer, D., Hell, M., and Jochum, W. (2011). HER2 genetic heterogeneity in breast carcinoma. J. Clin. Pathol. 64, 1112-1116.
45. Parra-Palau, J. L., Pedersen, K., Peg, V., Scaltriti, M., Angelini, P. D., and Escorihuela, M. (2010). A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers. Cancer Res. 70, 8537-8546.
46. Peddi, P. F., and Hurvitz, S. A. (2013). Trastuzumab emtansine: the first targeted chemotherapy for treatment of breast cancer. Future Oncol. 9, 319-326.
47. Pedersen, K., Angelini, P. D., Laos, S., Bach-Faig, A., Cunningham, M. P., and Ferrer-Ramon, C. (2009). A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol. Cell. Biol. 29, 3319-3331.
48. Pekmezci, M., Szpaderska, A., Osipo, C., and Ersahin, C. (2012). The effect of cold ischemia time and/or formalin fixation on estrogen receptor, progesterone receptor, and human epidermal growth factor receptor-2 results in breast carcinoma. Pathol. Res. Int. 2012, 947041.
49. Perez, E. A., Dueck, A. C., McCullough, A. E., Reinholz, M. M., Tenner, K. S., and Davidson, N. E. (2012). Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J. Natl. Cancer Inst. 104, 159-162.
50. Purnomosari, D., Aryandono, T., Setiaji, K., Nugraha, S. B., Pals, G., and van Diest, P. J. (2006). Comparison of multiplex ligation dependent probe amplification to immunohistochemistry for assessing HER-2/neu amplification in invasive breast cancer. Biotech. Histochem. 81, 79-85.
51. Recupero, D., Daniele, L., Marchio, C., Molinaro, L., Castellano, I., and Cassoni, P. (2013). Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. J. Pathol. 229, 390-399.
52. Reddy, J. C., Reimann, J. D., Anderson, S. M., and Klein, P. M. (2006). Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin. Breast Cancer 7, 153-157.
53. Regitnig, P., Schippinger, W., Lindbauer, M., Samonigg, H., and Lax, S. F. (2004). Change of HER-2/neu status in a subset of distant metastases from breast carcinomas. J. Pathol. 203, 918-926.
54. Risio, M., Casorzo, L., Redana, S., and Montemurro, F. (2005). HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment. Oncol. Rep. 13, 305-309.
55. Ross, J. S., Linette, G. P., Stec, J., Ross, M. S., Anwar, S., and Boguniewicz, A. (2003). DNA ploidy and cell cycle analysis in breast cancer. Am. J. Clin. Pathol. 120(Suppl.), S72-S84.
56. Rossi, V., Sarotto, I., Maggiorotto, F., Berchialla, P., Kubatzki, F., and Tomasi, N. (2012). Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer. Oncologist 17, 1418-1425.
57. Saez, R., Molina, M. A., Ramsey, E. E., Rojo, F., Keenan, E. J., and Albanell, J. (2006). p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin. Cancer Res. 12, 424-431.
58. Sapino, A., Montemurro, F., Marchio, C., Viale, G., Kulka, J., and Donadio, M. (2007). Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study. Ann. Oncol. 18, 1963-1968.
59. Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., and Cortes, J. (2007). Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl. Cancer Inst. 99, 628-638.
60. Schrohl, A. S., Pedersen, H. C., Jensen, S. S., Nielsen, S. L., and Brunner, N. (2011). Human epidermal growth factor receptor 2 (HER2) immunoreactivity: specificity of three pharmacodiagnostic antibodies. Histopathology 59, 975-983.
61. Shah, S. P., Roth, A., Goya, R., Oloumi, A., Ha, G., and Zhao, Y. (2012). The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399.
62. Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182.
63. Stephens, P. J., Tarpey, P. S., Davies, H., Van Loo, P., Greenman, C., and Wedge, D. C. (2012). The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400-404.
64. Sukov, W. R., Miller, D. V., Dueck, A. C., Tenner, K. S., Jenkins, R. B., and Kaufman, P. A. (2009). Benefit of adjuvant trastuzumab in breast cancer patients with focal HER2 amplified clones: data from N9831 Intergroup Adjuvant Trial. J. Clin. Oncol. 27, 520.
65. Szollosi, Z., Egervari, K., Nemes, Z., and Kaczur, V. (2005). Re: Lottner et al. simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J. Pathol. 205: 577-584; J. Pathol. 207, 119-120. [author reply 121-122].
66. Troxell, M. L., Bangs, C. D., Lawce, H. J., Galperin, I. B., Baiyee, D., and West, R. B. (2006). Evaluation of Her-2/neu status in carcinomas with amplified chromosome 17 centromere locus. Am. J. Clin. Pathol. 126, 709-716.
67. Tse, C. H., Hwang, H. C., Goldstein, L. C., Kandalaft, P. L., Wiley, J. C., and Kussick, S. J. (2011). Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy. J. Clin. Oncol. 29, 4168-4174.
68. Vance, G. H., Barry, T. S., Bloom, K. J., Fitzgibbons, P. L., Hicks, D. G., and Jenkins, R. B. (2009). Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines. Arch. Pathol. Lab. Med. 133, 611-612.
69. Varga, Z., Tubbs, R. R., Wang, Z., Sun, Y., Noske, A., and Kradolfer, D. (2012). Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer. Breast Cancer Res. Treat. 132, 925-935.
70. Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., and Baselga, J. (2012). Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783-1791.
71. Viale, G. (2009). Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer. J. Pathol. 219, 1-2.
72. Weigelt, B., and Reis-Filho, J. S. (2013). Activating mutations in HER2: neu opportunities and neu challenges. Cancer Discov. 3, 145-147.
73. White, S. J., Breuning, M. H., and den Dunnen, J. T. (2004). Detecting copy number changes in genomic DNA: MAPH and MLPA. Methods Cell Biol. 75, 751-768.
74. Wolff, A. C., Hammond, M. E., and Hayes, D. F. (2012). Re: predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J. Natl. Cancer Inst. 104, 957-958.
75. Wolff, A. C., Hammond, M. E., Schwartz, J. N., Hagerty, K. L., Allred, D. C., and Cote, R. J. (2007). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 25, 118-145.
76. Yeh, I. T., Martin, M. A., Robetorye, R. S., Bolla, A. R., McCaskill, C., and Shah, R. K. (2009). Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event. Mod. Pathol. 22, 1169-1175.
77. Yildiz-Aktas, I. Z., Dabbs, D. J., and Bhargava, R. (2012a). The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod. Pathol. 25, 1098-1105.
78. Yildiz-Aktas, I. Z., Dabbs, D. J., Cooper, K. L., Chivukula, M., McManus, K., and Bhargava, R. (2012b). The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Am. J. Clin. Pathol. 137, 691-698.
79. Zagozdzon, R., Gallagher, W. M., and Crown, J. (2011). Truncated HER2: implications for HER2-targeted therapeutics. Drug Discov. Today 16, 810-816.